Update of antiretroviral therapy for HIV infection

Infections in Medicine

Volumn 15, Issue 2, 1998, Pages 113-116

  Nadler, Jeffrey P ^a   Oehler, Richard L ^a   Holt, Douglas ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Human immunodeficiency virus (HIV); Non nucleoside reverse transcriptase inhibitors (NNRTIs); Nucleoside reverse transcriptase inhibitors (NRTIs); Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; ENZYME INHIBITOR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DIAGNOSTIC ACCURACY; DRUG MONITORING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROGNOSIS; PROTEIN DEGRADATION; RETROVIRUS; REVIEW; TREATMENT PLANNING;

EID: 0031980545     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122, 1995.
2. Ho DD, Neumann AU, Perelson AS, et al: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126, 1995.
3. Pantaleo G, Graziosi C, Demarest JF, et al: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of the disease. Nature 362:355-358, 1993.
4. Embretson J, Zupancic M, Ribas JL, et al: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-362, 1993.
5. Carpenter CCJ, Fischl MA, Hammer SM, et al: Antiretroviral therapy for HIV infection in 1997. JAMA 277:1962-1969, 1997.
6. Fischl MA, Richman DD, Grieco MH, et al: The efficiacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317:185-191, 1987.
7. Fischl MA, Richman DD, Hansen N, et al: The safety and efficacy of zidovudine (AZT) in the treatment of persons with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: A double-blind, placebo-controlled trial: The AIDS Clinical Trials Group. Ann Intern Med 112:727-737, 1990.
8. Volberding PA, Lagakos SW, Koch MA, et al: Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 322:941-949, 1990.
9. Hamilton JD, Hartigan PH, Simberkoff MS, et al: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 326:437-443, 1992.
10. Vella S, Giuliano M, Pezzotti P, et al: Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 267:1232-1236, 1992.
11. Cameron B, Heath-Chiozzi M, Kravci S, et al: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract LB6a.
12. Mellors JW, Muñoz A, Giorgi IV, et al: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126:946-954, 1997.
13. Hughes MD, Johnson VA, Hirsch MS, et al: Montoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral response. Ann Intern Med 126:929-938, 1997.
14. O'Brien WA, Hartingan PM, Doar ES, et al: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 126:939-945, 1997.
15. Volberding PA, Lagakos SW, Grimes JM, et al: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 333:401-407, 1995.
16. Cooper DA, Gatell JM, Kroon S, et al: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 329:297-303, 1993.
17. Gulick R, Mellors J, Havlir D, et al: Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract LB7.
18. 3. Abstracts from the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, Sept. 17-20, 1995. Abstract LB-1.
19. Gazzard B, Brun-Vezinet F, Loveday C: Further results from European/Australian Delta trial. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract LB5.
20. Eron JJ, Benoit SL, Jemsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662-1669, 1995.
21. Pollard R, Peterson D, Hardy D, et al: Anti-viral effect and safety of stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract 197.
22. Heath-Chiozzi M, Leonard J, Henry D, et al: Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract LB6b.
23. Kempf D, Marsh K, Denissen J, et al: Coadministration of ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. Abstracts from the 3rd Conference on Retrovirology and Opportunistic Infections, Washington, DC, Jan. 28-Feb. 1, 1996. Abstract 143.
24. Katzenstein D, Hammer S, Hughes M, et al: Plasma virion RNA in response to early antiretroviral drug therapy in ACTG 175: Do changes in virus load parallel clinical and immunologic outcome? Abstracts from the 35th ICAAC, San Francisco, Sept. 17-20, 1995. Abstract LB-2.